Novavax reports that their COVID-19 influenza combination vaccine is well tolerated, provides immune response
Novavax reports that their COVID-19 influenza combination vaccine is well tolerated, provides immune response

Novavax reports that their COVID-19 influenza combination vaccine is well tolerated, provides immune response

The company said yesterday that results from the clinical phase 1/2 study studying their COVID influenza combination vaccine (CIC) showed an immunological response and were safe. The preliminary experimental results showed that different CIC vaccine formulations induced immune responses in participants comparable to reference stand-alone influenza and stand-alone COVID-19 vaccine formulations (for H1N1, H3N2, B-Victoria HA and SARS-CoV). 2 rS antigens). Modeling results also showed that a combined formulation has the potential to reduce the total amount of antigen by up to 50% overall, optimizing production and delivery.

The preliminary results were presented at kl World Vaccine Congress Washington 2022 meeting this week.

“We are encouraged by these data and the potential path forward for a combination COVID-19 influenza vaccine as well as stand-alone influenza and COVID-19 vaccines,” Novavax President of Research and Development Gregory M. Glenn, MD, said in a statement.

The study vaccine combines the company’s COVID-19 vaccine, NVX-CoV2373, and its quadrivalent influenza vaccine candidate.

A model-based approach to experiment design was used to design the experiment, enabling more powerful fine-tuning of dose choices of both COVID-19 and influenza antigens for further development compared to traditional approaches.

The company is developing this combination vaccine with a view to having boosters needed on an annual basis.

“We continue to evaluate the dynamic public health landscape and believe that recurring boosters may be needed to combat both COVID-19 and seasonal influenza,” Glenn said.

At the aforementioned conference, Novavax reviewed key results from the Phase 3 trial with its stand-alone influenza candidate, which met its primary immunogenicity endpoint. These results were published earlier this year in The Lancet.

Leave a Reply

Your email address will not be published.